Bodor Laboratories Inc. Congratulates Kaken Pharmaceutical on Partnership with Dong Wha Pharmaceutical for Marketing Sofpironium Bromide in Korea

Miami, FL, June 23, 2023 – Bodor Laboratories Inc., a privately held pharmaceutical research and development company, proudly announces the latest achievement of its sublicensee, Kaken Pharmaceutical Co. Ltd., in forging a partnership with Dong Wha Pharmaceutical Co. Ltd., a leading Korean pharmaceutical company. This collaboration aims to market sofpironium bromide, a groundbreaking molecule discovered at Bodor Laboratories Inc., for the treatment of hyperhidrosis in Korea.

Dr. Nicholas Bodor, CEO and President of Bodor Laboratories Inc., expressed his satisfaction with the partnership, stating, “We are pleased with the continued success of Kaken Pharmaceutical in the further promotion of our molecule sofpironium bromide through their agreement with Dong Wha Pharmaceutical. Kaken’s impressive success in development and marketing of the molecule for hyperhidrosis (ECCLOCK®) in Japan positioned them well to partner with the prestigious Korean pharmaceutical company.”

Hyperhidrosis, a condition characterized by excessive sweating, affects millions of people worldwide and significantly impacts their quality of life. Sofpironium bromide, a result of Bodor Laboratories Inc.’s groundbreaking research, has shown immense potential in providing relief to those suffering from this debilitating condition. Through the partnership between Kaken Pharmaceutical and Dong Wha Pharmaceutical, this innovative treatment will now be made available to patients in Korea, ensuring improved healthcare options for individuals struggling with hyperhidrosis.
In addition to the success achieved in Korea, Bodor Laboratories Inc. remains optimistic about the progress of sofpironium bromide in the United States. The molecule is nearing market approval for the treatment of hyperhidrosis through the efforts of Botanix SB Inc., the licensee for Bodor Laboratories Inc.’s technology.
Dr. Nicholas Bodor highlighted the significant advancements in the United States, stating, “Our licensee for sofpironium bromide exclusively for hyperhidrosis, Botanix SB (a subsidiary of the Australian company Botanix Pharmaceuticals Co Ltd), has benefited immensely from the full clinical development of the drug by the previous licensee Fresh Tracks Therapeutics (formerly Brickell Biotech) and their continued support in guiding the NDA submission with the FDA. We look forward to the project’s likely approval this Fall and the subsequent marketing of the treatment by Botanix’s skilled team members.”
As Bodor Laboratories Inc. continues to witness the growing success and global adoption of sofpironium bromide, the company remains committed to advancing pharmaceutical research and development, with the ultimate goal of improving patients’ lives worldwide.

Bodor Laboratories Inc. is a pioneering privately held pharmaceutical research and development company founded in 2006 inspired by and based on Dr. Nicholas Bodor’s visionary Retrometabolic Drug Design (RMDD) concepts. This groundbreaking approach has been instrumental in the development of several revolutionary drugs, including highly successful therapies based on two molecules invented personally by Dr. Bodor: loteprednol etabonate (ALREX®, LOTEMAX®, ZYLET®) and sofpironium bromide (ECCLOCK®). With a steadfast commitment to advancing the field of medicine by employing drug design strategies that simultaneously increase both effectiveness and safety, Bodor Laboratories remains at the forefront of pharmaceutical research and development. We continuously harness the power of RMDD concepts to propel our pursuit of creating innovative therapeutics with the potential to transform lives. 

Our pipeline is built upon the foundation of existing approved therapies, which we are expanding to address a wide range of disease states, such as sialorrhea, COPD, and myopia. In addition to advancing the development of the soft anticholinergic class of molecules, exemplified by sofpironium bromide, we are also exploring the potential of a new generation of soft steroids to build upon the success of loteprednol etabonate.

For comprehensive information about Bodor Laboratories Inc., our innovative research and diverse pipeline, please visit or contact Elvie Guy at [email protected].

About Us

Bodor Laboratories, Inc. Founded in 2006 By Prof. Nicholas S. Bodor to Further the Development and Therapeutic Potential of his Novel Retrometabolic Drug Design and Targeting Concepts.



Get In Touch

4400 Biscayne Blvd, Suite 980
Miami, FL 33137

Phone: 305-571-8490
Fax: 305.571.8492
Email: [email protected]

Leading the way in safe drug design and delivery

© 2023 Bodor Laboratories. All rights reserved.